The preliminary unaudited total net product and net pre-product revenue arising from the sales of KIMMTRAK and tebentafusp was ~$50 million in Q4 2022, an increase of ~25% compared to the previous quarter, and ~$140 million for full year 2022. Preliminary unaudited cash and cash equivalents were ~$400 million USD year end 2022. In 2023, the Company will continue to launch in additional countries and establish KIMMTRAK globally as first line treatment for metastatic uveal melanoma, while exploring how to enhance patient convenience. In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMCR:
- Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
- Immunocore management to meet with BTIG
- Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
- Immunocore management to meet with Oppenheimer
- Immunocore named Top Pick for first half of 2023 at BTIG